Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGCD0103 in AML/MDS
NCT00374296Phase 2Terminated
- Sponsor
- Mirati Therapeutics
- Start
- Sep 2006
- Primary completion
- Sep 2008
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of mocetinostat in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Mirati Therapeutics. Primary endpoints: Safety and tolerability at 1 year and Response rate at 1 year. Started Sep 2006; status: terminated.
02
Drugs
mocetinostat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00374296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00374296.